Mark Sabag Sells 62,102 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Mark Sabag sold 62,102 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total value of $1,871,754.28. Following the sale, the insider directly owned 224,940 shares of the company’s stock, valued at approximately $6,779,691.60. This represents a 21.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $28.72 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock has a market capitalization of $33.02 billion, a P/E ratio of 23.93, a P/E/G ratio of 9.85 and a beta of 0.72. The company’s fifty day moving average is $32.66 and its two-hundred day moving average is $27.01. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Analysts remain constructive: a blended analyst target around $37.67 and multiple recent upgrades/target raises suggest upside vs. the current share price, supporting positive sentiment among buy-side and brokers. Brokerages Set Teva Price Target at $37.67
• Positive Sentiment: Teva published its Q1 2026 Aide Memoire on the investor site — this consolidates prior public disclosures and reduces surprise risk ahead of Q1 results, which can limit downside from unexpected disclosures. Teva Releases Q1 2026 Aide Memoire
• Neutral Sentiment: Teva set a firm date for Q1 2026 results: press release on April 29 at 7:00 a.m. ET followed by a conference call/webcast at 8:00 a.m. ET — gives investors a clear roadmap to reprice the stock on confirmed quarterly metrics and management commentary. Teva to Host Q1 2026 Conference Call
• Negative Sentiment: Insider selling: Mark Sabag sold 62,102 shares on March 17 at an average $30.14 (≈$1.87M), trimming his stake by ~21.6% — significant insider sales can hurt near-term sentiment even if they are for personal/liquidity reasons. Insider Sale Disclosure — Mark Sabag

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TEVA. Global Retirement Partners LLC lifted its position in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after acquiring an additional 292 shares during the last quarter. Captrust Financial Advisors raised its position in shares of Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after purchasing an additional 302 shares during the period. Banque Cantonale Vaudoise lifted its holdings in shares of Teva Pharmaceutical Industries by 6.3% during the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock valued at $160,000 after purchasing an additional 306 shares during the last quarter. Ethic Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 1.8% during the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock valued at $566,000 after purchasing an additional 325 shares during the last quarter. Finally, Allworth Financial LP boosted its position in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

TEVA has been the topic of a number of analyst reports. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Barclays raised their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Jefferies Financial Group upped their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.